Skip to main content
. 2020 Sep 29;124(2):368–374. doi: 10.1038/s41416-020-01075-1

Table 1.

Outcomes of patients with metastatic disease treated in AGCCCG SMDT: analysed by timea.

2006–2010 2011–2015 2006–2010 2011–2015
N PFS (2 years) PFS (2 years) p value N OS (5 years) OS (5 years) p value
Good 265 89.8% 93.0% 0.17 290 93.7% 94.7% 0.196
Intermediate 50 68.6% 71.8% 0.52 38 67.9% 83.6% 0.363
Poor 57 65.2% 50.6% 0.095 59 69.0% 59.2% 0.67

aThis includes patients with missing/unclear histology but allocated to an IGCCCG prognostic group (N = 4).